João Faro Viana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
João Faro Viana has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Mendes
Clinical Pathology Department, Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Portugal
1 shared publicationAna Brennand
IGC, Instituto Gulbenkian de Ciência, Oeiras, Portugal
1 shared publication- Ana Luísa Papoila
Epidemiology and Statistics Unit, Research Center, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal
1 shared publication Ana M. Casaca
CHLO, Centro Hospitalar de Lisboa Ocidental, Serviço de Patologia Clínica, Lisbon, Portugal
1 shared publication- Ana Sofia Correia
Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental; CEDOC, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal
1 shared publication - André Weigert
Renal Transplantation Unit, Nephrology Department, Hospital de Santa Cruz, Unidade Local de Saúde de Lisboa Ocidental, 2790-134 Carnaxide, Portugal
1 shared publication
Latest Publications
- 23 November 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (12) , e14825
Torquetenovirus viral load is associated with anti‐spike antibody response in SARS‐CoV‐2 mRNA BNT162b2 vaccinated kidney transplant patients
Introduction: Kidney transplant patients (KT) are at high risk for severe COVID‐19 and presented attenuated antibody responses to vaccination when compared to immunocompetent individuals. Torquetenovirus (TTV) has recently gained attention as a potential surrogate marker of the net state of immunosuppression. We evaluated the association between pre‐vaccination TTV viral load and anti‐spike total antibody response to SARS‐CoV‐2 vaccination in KT.Material and Methods: The 114 adult KT recipients enrolled in this prospective single‐center cohort study received two doses of SARS‐CoV‐2 mRNA BNT162b2 vaccine. Serum samples were collected immediately before vaccination at the days when patients received both the first (T0) and the second dose (T1) and 16–45 days after the second dose (T2). Primary endpoint was the development of anti‐spike total antibodies after vaccination. Demographic, clinical, and laboratorial parameters were compared between patients with and without detectable SARS‐CoV‐2 antibodies at T2.Results: Ninety‐nine patients (86.8%) were naïve for SARS‐CoV‐2 before vaccination. Fifty‐six (56.6%) patients developed anti‐spike total antibodies at T2. The use of mTOR inhibitors was associated with a favorable response (p = .005); conversely, mycophenolic acid (MPA) was associated with a negative response (p = .006). In a multivariable model, the presence of TTV at T0 ≥ 3.36 log10 cp/ml was associated with unfavorable vaccine response (OR: 5.40; 95% CI: 1.47–19.80; p = .011), after adjusting for age and eGFR at T0.Conclusions: Higher TTV viral loads before vaccination are associated with reduced anti‐spike total antibody response in SARS‐CoV‐2 mRNA BNT162b2 vaccinated KT patients. The association between TTV viral load and vaccine response may be an added‐value in the optimization of vaccination regimens in KT.
- 23 November 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (12) , e14825
Torquetenovirus viral load is associated with anti‐spike antibody response in SARS‐CoV‐2 mRNA BNT162b2 vaccinated kidney transplant patients
Introduction: Kidney transplant patients (KT) are at high risk for severe COVID‐19 and presented attenuated antibody responses to vaccination when compared to immunocompetent individuals. Torquetenovirus (TTV) has recently gained attention as a potential surrogate marker of the net state of immunosuppression. We evaluated the association between pre‐vaccination TTV viral load and anti‐spike total antibody response to SARS‐CoV‐2 vaccination in KT.Material and Methods: The 114 adult KT recipients enrolled in this prospective single‐center cohort study received two doses of SARS‐CoV‐2 mRNA BNT162b2 vaccine. Serum samples were collected immediately before vaccination at the days when patients received both the first (T0) and the second dose (T1) and 16–45 days after the second dose (T2). Primary endpoint was the development of anti‐spike total antibodies after vaccination. Demographic, clinical, and laboratorial parameters were compared between patients with and without detectable SARS‐CoV‐2 antibodies at T2.Results: Ninety‐nine patients (86.8%) were naïve for SARS‐CoV‐2 before vaccination. Fifty‐six (56.6%) patients developed anti‐spike total antibodies at T2. The use of mTOR inhibitors was associated with a favorable response (p = .005); conversely, mycophenolic acid (MPA) was associated with a negative response (p = .006). In a multivariable model, the presence of TTV at T0 ≥ 3.36 log10 cp/ml was associated with unfavorable vaccine response (OR: 5.40; 95% CI: 1.47–19.80; p = .011), after adjusting for age and eGFR at T0.Conclusions: Higher TTV viral loads before vaccination are associated with reduced anti‐spike total antibody response in SARS‐CoV‐2 mRNA BNT162b2 vaccinated KT patients. The association between TTV viral load and vaccine response may be an added‐value in the optimization of vaccination regimens in KT.
- Open Access
- 10 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-8
Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
- 10 January 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-8
Open AccessPopulation homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges
While mRNA vaccines are administrated worldwide in an effort to contain the COVID-19 pandemic, the heterogeneity of the humoral immune response they induce at the population scale remains unclear. Here, in a prospective, longitudinal, cohort-study, including 1245 hospital care workers and 146 nursing home residents scheduled for BNT162b2 vaccination, together covering adult ages from 19 to 99 years, we analyse seroconversion to SARS-CoV-2 spike protein and amount of spike-specific IgG, IgM and IgA before vaccination, and 3-5 weeks after each dose. We show that immunogenicity after a single vaccine dose is biased to IgG, heterogeneous and reduced with increasing age. The second vaccine dose normalizes IgG seroconversion in all age strata. These findings indicate two dose mRNA vaccines is required to reach population scale humoral immunity. The results advocate for the interval between the two doses not to be extended, and for serological monitoring of elderly and immunosuppressed vaccinees.
- 1 October 2020
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 347, 577355
Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse
- 1 October 2020
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 347, 577355
Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse